The present invention provides a method for detecting and treating hematologic malignancies including leukemia such as acute lymphoblastic leukemia (ALL) in a subject and a method for determining disease prognosis among leukemia patients by detecting CD9 expression. A kit and device useful for such methods are also provided. In addition, the present invention provides a composition for treating hematologic malignancies such as leukemia by suppressing CD9 expression or activity.

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.

Treatment of multiple myeloma with a combination of panobinostat and bortezomib at specified doses adjusted for safety.

A method of detecting the presence of glioblastomas and/or recurrent glioblastomas in a subject in need thereof includes isolating CD14+ cells from a blood sample of the subject and determining the ratio of isolated CD14+ cells expressing low levels of HLA-DR to isolated CD14+ cells expressing VNN2, wherein the subject has increased risk of glioblastomas or recurrent glioblastoma if the ratio of isolated CD14+ cells expressing low levels of HLA-DR to isolated CD14+ cells expressing VNN2 is greater than about 2.

A method for treating cancer and gold(III) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(III) complexes and a method of synthesizing the gold(III) complexes.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula:

##STR00001##

or salts thereof, wherein n is an integer from 12 to 24; and R.sub.2 is N.sup.+(CH.sub.3).sub.3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R.sub.1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R.sub.1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

A method for treating cancer and gold(III) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(III) complexes and a method of synthesizing the gold(III) complexes.

Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof.

Provided herein are methods for treating cancer relating to inhibition of PI3K, as pharmaceutical compositions comprising a PI3K inhibitor and a PAK1 inhibitor.